Walter Ombeni1, Appolinary R Kamuhabwa2. 1. Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 2. Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania akamuhabwa@muhas.ac.tz enali2012@gmail.com.
Abstract
OBJECTIVE: To determine the prevalence of dyslipidemia in HIV-infected patients using the first-line antiretroviral (ARV) drugs triple regimen. METHODS: HIV-infected patients aged ≥15 years and attending Care and Treatment Clinic (CTC) at Muhimbili National Hospital, in Dar es Salaam, Tanzania, were recruited for the study. Blood samples from patients were collected during their regular visits at the CTC and assayed for determination of total cholesterol, triglycerides (TGs), high-density lipoprotein, low-density lipoprotein cholesterol, and CD4 counts. RESULTS: The median CD4 count was 346 cells/mm(3) (2-2600). Triple therapy combinations of ARV drugs used by patients included zidovudine (ZDV)/lamivudine (3TC)/efavirenz (EFV; 42.4%), ZDV/3TC/nevirapine (NVP; 33.8%), tenofovir (TDF)/emtricitabine/EFV (19.9%), and TDF/3TC/EFV (3.9%). The overall prevalence of dyslipidemia in patients was 77.5%. There were varied prevalence of derangement of individual lipids among patients. Age, body mass index, CD4 count, sex, and duration of ARV drug use were the predictors of poor lipid profiles. CONCLUSION: The findings of this study indicate the need for routine monitoring of lipids among HIV-infected patients.
OBJECTIVE: To determine the prevalence of dyslipidemia in HIV-infectedpatients using the first-line antiretroviral (ARV) drugs triple regimen. METHODS:HIV-infectedpatients aged ≥15 years and attending Care and Treatment Clinic (CTC) at Muhimbili National Hospital, in Dar es Salaam, Tanzania, were recruited for the study. Blood samples from patients were collected during their regular visits at the CTC and assayed for determination of total cholesterol, triglycerides (TGs), high-density lipoprotein, low-density lipoprotein cholesterol, and CD4 counts. RESULTS: The median CD4 count was 346 cells/mm(3) (2-2600). Triple therapy combinations of ARV drugs used by patients included zidovudine (ZDV)/lamivudine (3TC)/efavirenz (EFV; 42.4%), ZDV/3TC/nevirapine (NVP; 33.8%), tenofovir (TDF)/emtricitabine/EFV (19.9%), and TDF/3TC/EFV (3.9%). The overall prevalence of dyslipidemia in patients was 77.5%. There were varied prevalence of derangement of individual lipids among patients. Age, body mass index, CD4 count, sex, and duration of ARV drug use were the predictors of poor lipid profiles. CONCLUSION: The findings of this study indicate the need for routine monitoring of lipids among HIV-infectedpatients.
Authors: Dayane C Souza; Pollyana M Nunhes; Wagner J R Domingues; Kauana Marchini; Lucas Hey; Jairo A Berti; Michele C C Trindade; Ademar Avelar Journal: Int J Exerc Sci Date: 2020-02-01
Authors: Benson M Hamooya; Patrick Musonda; Wilbroad Mutale; Sepiso K Masenga; Hikabasa Halwiindi; Katongo H Mutengo; Kaseya O R Chiyeñu; Gershom Chongwe; John R Koethe; Loren Lipworth; Douglas C Heimburger Journal: PLoS One Date: 2021-02-16 Impact factor: 3.240
Authors: Silvia A Guillemi; Sean H Ling; Julia S Dahlby; Benita Yip; Wendy Zhang; Mark W Hull; Viviane Dias Lima; Robert S Hogg; Ronald Werb; Julio S Montaner; Marianne Harris Journal: J Int AIDS Soc Date: 2016-09-09 Impact factor: 5.396
Authors: David Sando; Alexander Kintu; Samson Okello; Peter Chris Kawungezi; David Guwatudde; Gerald Mutungi; Winnie Muyindike; Nicolas A Menzies; Goodarz Danaei; Stéphane Verguet Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 6.707